Altium Capital Management LLC bought a new stake in shares of ESSA Pharma Inc. (NASDAQ:EPIX - Free Report) TSE: EPI in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm bought 1,428,000 shares of the company's stock, valued at approximately $2,556,000. Altium Capital Management LLC owned 3.22% of ESSA Pharma at the end of the most recent reporting period.
Other institutional investors also recently bought and sold shares of the company. Aldebaran Capital LLC purchased a new position in shares of ESSA Pharma in the fourth quarter valued at approximately $712,000. FNY Investment Advisers LLC purchased a new position in ESSA Pharma in the 4th quarter valued at approximately $44,000. BML Capital Management LLC acquired a new position in shares of ESSA Pharma in the fourth quarter worth $7,557,000. Lepercq Multi Asset Fund purchased a new stake in shares of ESSA Pharma during the fourth quarter worth $54,000. Finally, Magnus Financial Group LLC acquired a new stake in shares of ESSA Pharma in the fourth quarter valued at $99,000. 75.12% of the stock is owned by institutional investors and hedge funds.
ESSA Pharma Stock Performance
NASDAQ EPIX remained flat at $1.78 during trading hours on Wednesday. The company's stock had a trading volume of 47,119 shares, compared to its average volume of 325,087. The firm has a market capitalization of $79.01 million, a price-to-earnings ratio of -2.58 and a beta of 1.61. The company's 50-day simple moving average is $1.63 and its 200 day simple moving average is $2.23. ESSA Pharma Inc. has a 12 month low of $1.40 and a 12 month high of $7.88.
ESSA Pharma (NASDAQ:EPIX - Get Free Report) TSE: EPI last issued its earnings results on Tuesday, February 11th. The company reported ($0.19) earnings per share for the quarter, missing the consensus estimate of ($0.18) by ($0.01). Equities analysts expect that ESSA Pharma Inc. will post -0.42 EPS for the current fiscal year.
ESSA Pharma Company Profile
(
Free Report)
ESSA Pharma Inc, a clinical stage pharmaceutical company, focuses the development of small molecule drugs for the treatment of prostate cancer. The company's lead candidate EPI-7386, an androgen receptor based resistance mechanisms that develop in patients with castration-resistant prostate cancer and metastatic castration-resistant prostate cancer.
Recommended Stories
Before you consider ESSA Pharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ESSA Pharma wasn't on the list.
While ESSA Pharma currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
